Effects of beraprost sodium on improvement of insulin resistance in patients with type 2 diabetes and peripheral arterial disease

Effects of beraprost sodium on improvement of insulin resistance in patients with type 2 diabetes and peripheral arterial disease - Effects of beraprost sodium on improvement of insulin resistance in patients with type 2 diabetes and peripheral arterial disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003089

Enrollment

Registered

2010-01-25

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with type 2 diabetes and peripheral arterial disease

Interventions

Oral beraprost sodium for 12 weeks for patients with type 2 diabetes and peripheral arterial disease

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes HbA1c<8% BMI>=25 or "Male Waist>=85cm or Female Waist>=90cm" with untreated peripheral arterial disease

Exclusion criteria

Exclusion criteria: - Patients with bleeding tendancy - Patients with severe renal dysfunction - Patients with liver dysfunction - Patients with a past hystory of drug hypersensitivity - Pregnant women or women with breast-feeding - Patients who took prostaglandin derivatives within 3 months

Design outcomes

Primary

Measure	Time frame
Glucose infusion rate on euglycemic hyperinsulinemic clamp (0, 12 weeks)	—

Countries

Japan

Contacts

Public ContactHisayuki Katsuyama

Graduate School of Medicine, University of Tokyo Department of Metabolic Diseases

katsuyama-hs@umin.ac.jp03-5800-8818

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026